Evidence-Based Biomarker Identification
It can be a challenge to identify the target biomarkers for NGS panel design. All too often, a manual research process misses important biomarkers tied to a specific disease or includes poorly coorelated targets that can’t be backed up with clinical evidence. Our Evidence-Based Panel Design process identifies biomarker candidates for NGS panels by objectively correlating genes and variants with the quality and frequency of citations in the scientific literature. The deliverable is a list of scientifically curated biomarkers associated with a specific disease including supporting citations. Contact us to learn more about how we can accelerate your next evidence-based panel design.
Our specialists review and rank the candidate biomarkers and reference citations before your final approval.
Supporting Literature Citations
Each biomarker target for your NGS panel includes the top ranking literature citations.
Download White Paper to Learn More About Evidence-Based Biomarker Selection
Learn how to select biomarkers for an NGS panel based on evidence found in the scientific literature. This white paper shows how evidence-based gene panels are designed with an example pan-hematopoietic malignancy panel including 314 genes associated with leukemia and 311 genes associated with lymphoma.